Selexis And Generium Launch Omalizumab Biosimilar In Russia
Xolair Rival Is Third Biosimilar Developed By Firms With SUREtechnology Platform
Selexis and Generium have claimed the launch of an omalizumab biosimilar in Russia, with their Genolar version of Xolair marking the third biosimilar to be launched by the pair following development with Selexis’ SUREtechnology platform.
